Arcus Biosciences (RCUS) Set to Announce Earnings on Tuesday

Arcus Biosciences (NYSE:RCUS) is anticipated to post its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect Arcus Biosciences to announce earnings of ($0.8824) per share and revenue of $8.78 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:00 PM ET.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.17. The business had revenue of $41.00 million for the quarter, compared to the consensus estimate of $21.98 million. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The firm’s revenue was down 74.4% compared to the same quarter last year. On average, analysts expect Arcus Biosciences to post ($3.52) EPS for the current fiscal year and ($3.15) EPS for the next fiscal year.

Arcus Biosciences Trading Up 0.1%

Shares of Arcus Biosciences stock opened at $22.14 on Tuesday. The company’s fifty day simple moving average is $26.83 and its 200-day simple moving average is $26.24. The stock has a market capitalization of $2.82 billion, a PE ratio of -5.68 and a beta of 0.94. Arcus Biosciences has a 1-year low of $16.35 and a 1-year high of $31.74. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.82 and a quick ratio of 3.82.

Insiders Place Their Bets

In other Arcus Biosciences news, CAO Alexander Azoy sold 2,827 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $30.00, for a total value of $84,810.00. Following the completion of the transaction, the chief accounting officer directly owned 39,581 shares in the company, valued at $1,187,430. This represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

RCUS has been the subject of several analyst reports. William Blair initiated coverage on Arcus Biosciences in a research note on Friday. They issued an “outperform” rating for the company. Truist Financial reiterated a “buy” rating and set a $40.00 target price (up from $35.00) on shares of Arcus Biosciences in a research report on Tuesday, September 8th. Morgan Stanley set a $23.00 price target on Arcus Biosciences in a report on Monday, August 10th. The Goldman Sachs Group restated a “buy” rating and issued a $42.00 price target on shares of Arcus Biosciences in a research report on Friday, August 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Thursday. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.55.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc is a biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses a proprietary research platform to develop small-molecule and antibody-based therapies designed to target biological mechanisms involved in tumor growth and immune-system regulation.

Arcus’ oncology pipeline has included investigational therapies such as zimberelimab, an anti-PD-1 antibody; domvanalimab, an anti-TIGIT antibody; quemliclustat, a CD73 inhibitor; and etrumadenant, an adenosine receptor antagonist.